Latest Tax Incentives News

Aruma Resources has confirmed maiden drilling plans at its Fiery Creek Copper Project in Queensland and secured $900,000 in a recent placement to accelerate exploration across its portfolio.

Percheron Therapeutics has licensed HMBD-002, a promising immuno-oncology candidate, completed FDA IND transfer, and plans to launch phase II trials in 2026. The company also reported a solid cash position and issued loyalty options to shareholders.

Zelira Therapeutics reports promising diabetic neuropathy study results with ZLT-L-007 surpassing Lyrica, while converting $3.25 million in notes to equity to bolster HOPE® 1 clinical development.

Alterity Therapeutics has secured U.S. FDA Fast Track designation for its drug ATH434 targeting Multiple System Atrophy, supported by promising Phase 2 clinical trial data showing slowed disease progression and a solid safety profile.

Cynata Therapeutics is advancing three pivotal clinical trials targeting acute Graft versus Host Disease, osteoarthritis, and kidney transplantation, with major results expected through early 2026. The company maintains a solid cash position supporting its clinical pipeline and strategic growth.

CurveBeam AI reported a solid 18% increase in purchase orders for FY25, alongside record cash receipts and positive operational cash flow in Q4. The company is also advancing a significant vendor financing facility to support growth in key markets.

Identitii Limited has refinanced a $0.8 million loan with an interest-free facility from its largest shareholder, Beauvais Capital, reducing interest expenses and freeing up company assets.

CurveBeam AI reported a strong Q4 FY25 with record customer receipts and an 18% rise in purchase orders, while advancing key regulatory milestones and securing a major financing facility.

Critica Limited reports significant progress on its Jupiter Rare Earths Project, unveiling a 95% mass reduction in beneficiation testwork and appointing a new CEO to drive development.

Acrux Limited reports promising revenue growth driven by new topical generic launches in the US and secures crucial RDTI funding, marking a strategic shift under new CEO John Warmbrunn.

Actinogen Medical has reached a key milestone in its XanaMIA phase 2b/3 Alzheimer’s trial with over 100 participants enrolled, setting the stage for an interim analysis in January 2026. The company also secured a $13.8 million non-dilutive R&D funding facility to support ongoing development.

Avecho Biotechnology has ramped up recruitment in its pivotal Phase III insomnia trial and is advancing plans for regulatory approval and commercialization of its TPM®-enhanced CBD capsule, aiming to be the first over-the-counter CBD insomnia treatment in Australia.